

ESC Declaration of Interest Report
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines and documents developed under the auspices of the ESC Clinical Practice Guidelines Committee to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of these documents.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

This is a focused update of 2021 Guidelines and the applicable DOI assessment criteria are the same as those of the 2021 Guidelines.

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Adamo Marianna	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : SPEAKER FEES Abbott Vascular : SPEAKER FEES
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
Baumbach Andreas	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Antiplatelet Faraday : Infarct size reduction Microport : Stents Sinomed : Stents Medtronic : Valves Pi-Cardia : Valves Research funding (personal) from healthcare industry. Abbot Vascular : OCT
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Acute Coronary Syndromes Faraday : Acute Coronary Syndromes Microport : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sinomed : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Valvular Heart Disease Pi-Cardia : Valvular Heart Disease

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Boehm Michael	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Abbott : Cardiology</p> <p>Amgen : Cardiology</p> <p>Astra Zeneca : Cardiology</p> <p>Bayer : Cardiology</p> <p>Boehringer-Ingelheim : Cardiology</p> <p>Medtronic : Cardiology</p> <p>Novartis : Cardiology</p> <p>Servier : Cardiology</p> <p>Vifor International : Cardiology</p> <p>Bristol Myers Squibb : Cardiology</p> <p>Cytokinetics : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Abbott : Chronic Heart Failure, Hypertension</p> <p>Amgen : Chronic Heart Failure, Hypertension</p> <p>Astra Zeneca : Chronic Heart Failure, Hypertension</p> <p>Bayer : Chronic Heart Failure, Hypertension</p> <p>Boehringer-Ingelheim : Chronic Heart Failure, Hypertension</p> <p>Medtronic : Chronic Heart Failure, Hypertension</p> <p>Novartis : Chronic Heart Failure, Hypertension</p> <p>Servier : Chronic Heart Failure, Hypertension</p> <p>Vifor International : Chronic Heart Failure, Hypertension</p> <p>Bristol Myers Squibb : Chronic Heart Failure, Hypertension</p> <p>Cytokinetics : Chronic Heart Failure, Hypertension</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Burri Haran	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : CIED consultancy Abbott : CIED education Medtronic : CIED education Biotronik : CIED education Microport : CIED education</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : CIED Boston Scientific : CIED Medtronic : CIED Biotronik : CIED</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Device Therapy Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy</p>
Butler Javed	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Heart Failure Astra Zeneca : Heart Failure Janssen-Cilag : Heart Failure Medtronic : Heart Failure Novartis : Heart Failure Pfizer : Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Impulse Dynamics : Heart Failure Vifor International : Heart Failure Amgen Inc : Heart Failure Bristol Myers Squibb : Heart Failure Merck Sharp & Dohme : Heart Failure Bayer AG : Heart Failure Roche Diagnostics : Heart Failure NovoNordisk : Heart Failure Cardiac Dimensions : Heart Failure Boehringer Ingelheim : Heart Failure Llvanova : Heart Failure Adrenomed : Heart Failure Innolife : Heart Failure Applied Therapeutics : Heart Failure G3 Pharmaceutical : Heart Failure American Regent : Heart Failure CVRx, : Heart Failure Occulotech : Heart Failure Sequanna : Heart Failure</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Edwards Lifesciences : Chronic Heart Failure Eli Lilly : Chronic Heart Failure Janssen-Cilag : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	Medtronic : Chronic Heart Failure
	Novartis : Chronic Heart Failure
	Pfizer : Chronic Heart Failure
	Sanofi Aventis : Chronic Heart Failure
	Impulse Dynamics : Chronic Heart Failure
	Vifor International : Chronic Heart Failure
	Amgen Inc : Chronic Heart Failure
	Bristol Myers Squibb : Chronic Heart Failure
	Merck Sharp & Dohme : Chronic Heart Failure
	Occlutech : Chronic Heart Failure
	CVRx : Chronic Heart Failure
	Bayer AG : Chronic Heart Failure
	Roche Diagnostics : Chronic Heart Failure
	NovoNordisk : Chronic Heart Failure
	Cardiac Dimensions : Chronic Heart Failure
	Inventiva : Chronic Heart Failure
	LIvanova : Chronic Heart Failure
	Adrenomed : Chronic Heart Failure
	Cytokinetics : Chronic Heart Failure
	Innolife : Chronic Heart Failure
	Johnson and Johnson : Chronic Heart Failure
	Lexicon : Chronic Heart Failure
	Pharmacosmos : Chronic Heart Failure
	American Regent : Chronic Heart Failure
	Arca : Chronic Heart Failure
	Sequanna : Chronic Heart Failure

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Celutkiene Jelena	2021	<p>Applied Therapeutic : Chronic Heart Failure CardiorPharma : Chronic Heart Failure Element : Chronic Heart Failure Imbria : Chronic Heart Failure</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Voting member of the US FDA Cardio-Renal Advisory Committee. Editorial Board, JACC. Just completed my term as chair of scientific statements committee for the Heart Failure Society of America</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : anticoagulation Boehringer-Ingelheim : heart failure Novartis : heart failure Bayer Healthcare : heart failure Astrazeneca : heart failure</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiovascular Disease in Special Populations Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Astrazeneca : Chronic Heart Failure</p>
Chioncel Ovidiu	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Advisory Board Heart Failure</p>
	2022	<p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cleland John	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. NI Medical : Bio-impedance Philips : Cardiac Imaging Amgen : Heart Failure Astra Zeneca : heart failure Medtronic : Heart Failure Novartis : Heart Failure Servier : Heart Failure Johnson & Johnson : Heart Failure Bayer Healthcare : Heart Failure Torrent : heart failure Vifor International : Heart Failure Bristol Myers Squibb : heart failure Respicardia : heart failure Roche Diagnostics : Heart Failure Sensible Medical : Heart Failure corvidia : Heart Failure Abbott : Heart failure devices and biomarkers</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : CV Disease Amgen : Heart Failure Novartis : Heart failure Philips : Heart Failure Vifor International : Heart Failure Bristol Myers Squibb : heart failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Moderna : Heart Failure Janssen-Cilag : Heart Failure / Pulmonary Hypertension Medtronic : Heart failure devices CVRx : Heart failure devices Idorsia : Hypertension Pharmacosmos : IV Iron Pharmanord : Nutritional supplements</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer Healthcare : CV Disease Amgen : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Philips : Heart Failure Vifor International : Heart Failure Roche Diagnostics : Heart Failure MyoKardia : Heart Failure Thermofisher : Heart Failure Pharmacosmos : Heart Failure Viscardia : Heart Failure - Devices</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - HEART FAILURE - Share options in HeartFelt technologies developing a device for measuring limb volume and congestion (CE marked; no trial data as yet). Share options in Viscardia developing a diaphragmatic pacing device (Phase IIa). Share options in PharmaIn developing developing new investigational medical products (Phase I)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. I have helped support "Pumping Marvellous", a patient advocacy organisation based in the UK. I am a member of the British Society for Heart Failure.</p>
2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator,</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>committee member, etc. Abbott : Chronic Heart Failure Amgen : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Edwards Lifesciences : Chronic Heart Failure Medtronic : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure Servier : Chronic Heart Failure Johnson & Johnson : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Torrent : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure Sensible Medical : Chronic Heart Failure NI Medical : Chronic Heart Failure CorVia : Chronic Heart Failure Innolife : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Moderna : Chronic Heart Failure CSL Vifor International : Chronic Heart Failure Biopetetics : Chronic Heart Failure Olatec : Chronic Heart Failure Respicardia : Chronic Heart Failure, Diseases of the Aorta Philips : Echocardiography</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Amgen : Chronic Heart Failure Janssen-Cilag : Chronic Heart Failure Medtronic : Chronic Heart Failure Philips : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Vifor International : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure CVRx : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Pharmanord : Chronic Heart Failure Moderna : Chronic Heart Failure Idorsia : Hypertension Novartis : Peripheral Vascular and Cerebrovascular Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Viscardia : Analysis of a Clinical Trial, Senior Adviser Pharmacosmos : Support for the IRONMAN Trial, Investigator CSL Vifor International : Support for the RELIEHF RCT, Chief Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have stock options in HeartFelt, a company focussed on non-invasive, passive monitoring for peripheral oedema Viscardia, a company developing diaphragmatic synchronised pacing for heart failure.</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Crespo-Leiro Maria Generosa	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : heart failure Astra Zeneca : Heart Failure Boehringer-Ingelheim : Heart Failure Medtronic : Heart Failure Novartis : Heart failure Vifor International : heart failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : heart failure Novartis : heart failure Pfizer : heart failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Abbott : heart failure Novartis : Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
<p>Crespo-Leiro Maria Generosa</p>	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Vifor International : Chronic Heart Failure Takeda Pharmaceuticals : Chronic Heart Failure Medtronic : Device Therapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure Biotest : Chronic Heart Failure Abbott : Device Therapy</p>
<p>Farmakis Dimitrios T</p>	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Laboratories : Biomarkers (troponin) Leo Pharma : Cancer Bayer : Heart failure Boehringer-Ingelheim : Heart failure Novartis : Heart failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Farmakis Dimitrios T	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Acute Cardiac Care Leo Pharma : Cardiovascular Disease in Special Populations Myocardial Solutions : Cardiovascular Disease in Special Populations Boehringer-Ingelheim : Chronic Heart Failure Bayer : Pharmacology and Pharmacotherapy</p>
Gardner Roy Stuart	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : anticoagulation; empagliglozin Boston Scientific : Cardiac Rhythm Management Abbott Laboratories : Cardiac Rhythm Management Astra Zeneca : Dapagliflozin Novartis : Heart Failure Pharmacosmos : Iron</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : CRM Boston Scientific : CRM</p> <p>Research funding (personal) from healthcare industry. British Heart Foundation : Heart Failure (RHYTHM-HF) - I do NOT receive any of this grant as payment/salary</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. I work for the National Health Service (NHS), UK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am the director of Professor Gardner Heart Failure Consultancy (HFC) Ltd where honoraria from 1A are paid I am the Chair of the British Society for Heart Failure (BSH) I am on an endpoint committee for Myokardia 007</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gardner Roy Stuart	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure AnaCardio : Chronic Heart Failure Lumira : Chronic Heart Failure, Other Boston Scientific : Device Therapy Abbott Laboratories : Device Therapy, Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Abbott fund a clinical fellow in my department; they have also provided research support for a research project (RHYTHM-HF), Chief Investigator Boston Scientific : Research physiologist in my department, Heart failure research lead</p> <p>Research funding (personal) from healthcare industry. British Heart Foundation : RHYTHM-HF - why do patients with heart failure die?, Chief investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Chair of the British Society for Heart Failure (BSH) - voluntary</p>
Gilard Martine	<p>2021 Nothing to be declared</p> <hr/> <p>2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the board of French Society of Cardiology Member of the board of EAPCI Member of the nominating committee of ESC</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Heymans Stephane	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Advisory Board Biomarkers Novo-Nordisk : Advisory board. Cardiomyopathies Astra Zeneca : Consultancy on Early Clinical Development (preclinical stage till Phase II) in Cardiovascular, Renal and Metabolism. CSL Behring : Consultancy on Target Discovery in Myocarditis Novartis : Lectures fees on Cardiomyopathies</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : Amyloidosis</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Basic Science CSL Behring : Basic Science Pfizer : Research Methodology, Basic Science</p>
Hoes Arno	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : heart failure</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : History of Cardiology, Cardiovascular Nursing and Allied Professions</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : anticoagulants, vericiguat Astra Zeneca : antiplatelets, dapagliflozine Pfizer : Cardiomyopathies Takeda Pharmaceuticals : Cardiomyopathies Boehringer-Ingelheim : diabetes and CVD, empagliflozine Abbott : FMR in heart failure Servier : heart failure translational medicine academy : heart failure Cardiac Dimensions : heart failure devices Vifor International : IV iron Swixx Biopharma : iv iron Respicardia : phrenic nerve stimulation in CSA Novartis : sacubitril/valsartan</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Vifor International : iv iron</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Payment from University of Zurich for lectures during the Postgraduate HF Course. Payment from NCBIR (Polish public entity) for research activities in the area of telemedicine in heart failure and non coding RNA</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Cardiac Dimensions : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Servier : Chronic Heart Failure, Acute Heart Failure Vifor International : Chronic Heart Failure, Acute Heart Failure Swixx Biopharma : Chronic Heart Failure, Acute Heart Failure Takeda Pharmaceuticals : Chronic Heart Failure, Other Respicardia : Device Therapy, Chronic Heart Failure translational medicine academy : Device Therapy, Chronic Heart Failure, Acute Heart Failure Pfizer : Other Sanofi Aventis : Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lainscak Mitja	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Anticoagulation Boehringer-Ingelheim : Atrial fibrillation Astra Zeneca : Heart failure Novartis : Heart Failure Vifor International : Heart Failure Respicardia : Heart failure Sanofi Aventis : Hyperlipidemia Krka Pharma : Hypertension Abbott Laboratories : Nutrition</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - OTHER - Actimed</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure</p>
Lam Carolyn Sp	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Biomarkers ProSciento Inc : CRO / Heart Failure Trial Us2.ai : Digital Health/Medical Technology EchoNous Inc : Digital Health/Medical Technology Boston Scientific : Heart failure Novartis : Heart failure Servier : Heart Failure Sanofi Aventis : Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Impulse Dynamics : Heart Failure Abbott Laboratories : Heart Failure Merck Sharp & Dohme : Heart failure Novo-Nordisk : Heart failure Ionis pharmaceuticals : Heart Failure Cytokinetics : Heart Failure Applied Therapeutics : Heart failure Janssen Research & Development LLC : Heart failure Allysta Pharmaceuticals : Heart Failure AnaCardio AB : Heart Failure Recardio Inc : Heart Failure Bayer : Heart failure, Cardiorenal initiative, Vascular protection Boehringer Ingelheim : Heart failure, Diabetes Astrazeneca : Heart failure, Diabetes, Real world evidence Siemens Healthineers : Medical device Medscape : Medical Education Radcliffe Group Ltd : Medical education</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Roche Diagnostics : Biomarkers Bayer : Heart failure</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - IMAGING - Us2.ai (Co-founder and non-executive director)</p>
2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Chronic Heart Failure, Acute Heart Failure Eli Lilly : Chronic Heart Failure, Acute Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	Novartis : Chronic Heart Failure, Acute Heart Failure
	Servier : Chronic Heart Failure, Acute Heart Failure
	Impulse Dynamics : Chronic Heart Failure, Acute Heart Failure
	Bristol Myers Squibb : Chronic Heart Failure, Acute Heart Failure
	Merck Sharp & Dohme : Chronic Heart Failure, Acute Heart Failure
	Novo Nordisk : Chronic Heart Failure, Acute Heart Failure
	Boehringer Ingelheim : Chronic Heart Failure, Acute Heart Failure
	Ionis pharmaceuticals : Chronic Heart Failure, Acute Heart Failure
	Cytokinetics : Chronic Heart Failure, Acute Heart Failure
	Applied Therapeutics : Chronic Heart Failure, Acute Heart Failure
	Intellia Therapeutics : Chronic Heart Failure, Acute Heart Failure
	Janssen Research & Development : Chronic Heart Failure, Acute Heart Failure
	Bayer : Chronic Heart Failure, Acute Heart Failure, Other
	Roche Diagnostics : Chronic Heart Failure, Acute Heart Failure, Other
	Astrazeneca : Chronic Heart Failure, Acute Heart Failure, Other
	Boston Scientific : Device Therapy
	Edwards Lifesciences : Device Therapy, Chronic Heart Failure, Acute Heart Failure
	Recor Medical : Device Therapy, Chronic Heart Failure, Acute Heart Failure
	Siemens Healthineers : Device Therapy, Chronic Heart Failure, Acute Heart Failure
	Alleviant Medical : Device Therapy, Chronic Heart Failure, Acute Heart Failure
	EchoNous Inc : e-Cardiology/Digital Health
	Us2.ai : Echocardiography
	Radcliffe : Training and Education
	Medscape/WebMD LLC : Training and Education
	Research funding from healthcare industry under your direct/personal responsibility (to department or institution).
	Roche Diagnostics : Asian Diabetes Outcome Prevention Trial, Principal Investigator

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	<p style="text-align: center;">Type of Relationship with Industry</p> <p>Novo Nordisk : Clinical, imaging and biomarker data exploration in HFpEF patients from ATTRaCT cohort(s), Principal Investigator</p> <p>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <p>Healthcare - Echocardiography - Us2.ai (Co-founder and non-executive director)</p>
Lyon Alexander	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib</p> <p>Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib</p> <p>GlaxoSmithKline : Heart Failure</p> <p>Astra Zeneca : Heart Failure, Dapagliflozin</p> <p>Novartis : Heart failure, Entresto, breast cancer - ribociclib, MPN</p> <p>Ferring Pharmaceuticals : Prostate Cancer</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <p>Healthcare - HEART FAILURE - Stock option (<1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Janssen-Cilag : Cardiovascular Disease in Special Populations</p> <p>Novartis : Cardiovascular Disease in Special Populations</p> <p>Pfizer : Cardiovascular Disease in Special Populations</p> <p>Takeda Pharmaceuticals : Cardiovascular Disease in Special Populations</p> <p>Astellas : Cardiovascular Disease in Special Populations</p> <p>Ferring Pharmaceuticals : Cardiovascular Disease in Special Populations</p> <p>Astra Zeneca : Chronic Heart Failure</p> <p>GlaxoSmithKline : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
McDonagh Theresa	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Heart Failure Corpus : Heart Failure
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Boston Scientific : Chronic Heart Failure Edwards Lifesciences : Chronic Heart Failure
McMurray John J V	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Global Clinical Trial Partners Ltd (GCTP) : Director Abbott : Lecture fee Astra Zeneca : lecture fee Servier : lecture fee Boehringer Ingelheim : lecture fee Lupin : lecture fee Hikma : lecture fee Alkem Metabolics : lecture fee Eris Lifesciences : lecture fee Sun Pharmaceuticals : lecture fee Medscape/Heart.Org : lecture fee ProAdWise Communications : lecture fee Radcliff Cardiology : lecture fee The Corpus : lecture fee S & L Solutions Event Management Inc. : lecture fee Translational Medical Academy : lecture fee

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Alnylam : My employer, Glasgow University, has been paid by Alnylam Pharmaceuticals for my participation in a company advisory board about development of ALN-AGT01.</p> <p>Amgen Inc : My employer, Glasgow University, has been paid by Amgen for my time spent as Steering Committee member for the mecarbil (COSMIC-HF and GALACTIC-HF Trial steering committees). These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.</p> <p>Astrazeneca : My employer, Glasgow University, has been paid by AstraZeneca (who market dapagliflozin) for my time spent as Principal Investigator of DAPA-HF and Co-principal Investigator of DELIVER and DETERMINE (trials using dapagliflozin) in heart failure and meetings and other activities related to these trials. AstraZeneca has also paid my travel and accommodation for these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.</p> <p>Bayer : My employer, Glasgow University, has been paid by Bayer for my time spent as Steering Committee member for the PANACHE trial using neladenoson bialanate and for the FINEARTS trial with finerenone. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.</p> <p>Bristol Myers Squibb : My employer, Glasgow University, has been paid by BMS for my time spent as a Steering Committee member for the STAND-UP clinical trial (using a HNO donor) in heart failure and meetings related to this trial. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.</p> <p>Boehringer-Ingelheim : My employer, Glasgow University, has been paid by Boehringer-Ingelheim for my advice about development of empagliflozin as a potential therapy for heart failure.</p> <p>Cardurion : My employer, Glasgow University, has been paid by Cardurion for my participation in a company advisory board about development of a PDE 9 inhibitor in heart failure.</p> <p>Cytokinetics : My employer, Glasgow University, has been paid by Cytokinetics for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Cytokinetics has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.</p> <p>Dalcor : My employer, Glasgow University, has been paid by DalCor Pharmaceuticals for my time spent as Steering Committee member for the Dal-GenE trial and meetings/other activities related to this trial/treatment. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.</p> <p>GlaxoSmithKline : My employer, Glasgow University, has been paid by GSK for my time spent as Co-principal investigator and Steering Committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and meetings related to these trials. GSK has also paid my travel and accommodation for some of these meetings. These</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.</p> <p>Ionis : My employer, Glasgow University, has been paid by Ionis for my advice about development of ISIS757456 as a potential therapy for heart failure.</p> <p>KBP Biosciences : My employer, Glasgow University, has been paid by KBP Biosciences for my advice about development of KBP-5074 as a potential therapy for heart failure.</p> <p>Novartis : My employer, Glasgow University, has been paid by Novartis for my time spent as Executive Committee member and then co-principal investigator of ATMOSPHERE, co-principal investigator of the PARADIGM-HF and PARAGON-HF trials and Executive/Steering Committee member for PARADISE-MI, PERSPECTIVE and PARACHUTE-HF trials (with sacubitril/valsartan) and meetings/presentations related to these trials and aliskiren and sacubitril/valsartan. Novartis has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments from Novartis in relation to these trials/drugs.</p> <p>Theracos : My employer, Glasgow University, has been paid by Theracos for my time spent as Principal investigator for the BEST trial and meetings related to this trial. Theracos has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). British Heart Foundation : My Institute receives extensive funding as both a Centre of Research Excellence and for individual projects/programmes - this information is available of the institute website/in the annual reports https://www.gla.ac.uk/researchinstitutes/icams/</p> <p>Research funding (personal) from healthcare industry. British Heart Foundation , Chief Scientist Office (Scottish Government), American Heart Association and NIH funding - see https://www.gla.ac.uk/researchinstitutes/icams/staff/johnmcmurray/#/grants : not product specific</p> <hr/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure Lupin : Chronic Heart Failure Hikma : Chronic Heart Failure Alkem Metabolics : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Eris Lifesciences : Chronic Heart Failure Sun Pharmaceuticals : Chronic Heart Failure Medscape/Heart.Org : Chronic Heart Failure ProAdWise Communications : Chronic Heart Failure Radcliff Cardiology : Chronic Heart Failure The Corpus : Chronic Heart Failure Global Clinical Trial Partners Ltd (GCTP) : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure GlaxoSmithKline : Chronic Heart Failure Amgen Inc : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure Astrazeneca : Chronic Heart Failure Theracos : Chronic Heart Failure Ionis : Chronic Heart Failure Dalcor : Chronic Heart Failure Cytokinetics : Chronic Heart Failure Cardurion : Chronic Heart Failure KBP Biosciences : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). British Heart Foundation : My Institute receives extensive funding as both a Centre of Research Excellence and for individual projects/programmes, Grant holder</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mebazaa Alexandre	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Laboratories : biomarkers Roche Diagnostics : biomarkers 4TEEN4 : biomarkers Adrenomed : biomarkers, sepsis Novartis : Heart failure Orion : Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). 4TEEN4 : Biomarker, heart failure Roche Diagnostics : Biomarkers Adrenomed : biomarkers, sepsis</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Acute Cardiac Care Abbott Laboratories : Acute Cardiac Care Merck Sharp & Dohme : Acute Cardiac Care Bayer AG : Acute Cardiac Care Roche Diagnostics : Acute Cardiac Care Corteria Pharmaceuticals : Acute Cardiac Care S-form Pharma : Acute Cardiac Care</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). 4TEEN4 : animal and in vitro research to decipher mechanisms, principal investigator Roche Diagnostics : set up a biobank and clinical trial, principal investigator</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Metra Marco	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra-Zeneca : Advisory boards fee and speaker's fees Boehringer-Ingelheim : As member of advisory boards Actelion : As member of Data Monitoring Committee of SERENADE trial Llvanova : Data Monitoring Committee member Vifor Pharma : Executive committee member of AFFIRM -AHF and DIAMOND-HF trial Amgen : Member of the Executive committee of one trial, GALACTIC-HF Abbott Vascular : Speaker's fees Edwards Therapeutics : Speaker's fees</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Chronic Heart Failure Abbott Vascular : Chronic Heart Failure Bayer AG : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Vifor International : Chronic Heart Failure, Acute Heart Failure Roche Diagnostics : Chronic Heart Failure, Acute Heart Failure Edwards Lifesciences : Valvular Heart Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Abbott Vascular : Valvular Heart Disease</p>
Mindham Richard	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mindham Richard	2021	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Muneretto Claudio	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Atricure : Atrial fibrillation</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Llvanova : Heart valve</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Atricure : Atrial Fibrillation (AF)</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. CORCYM : Cardiovascular Surgery</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Speaker fee, consultancy Boehringer Ingelheim : Speaker fee, consultancy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. CHF Solutions : Aquapheresis Therapy in heart failure</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo Nordisk : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Menarini, : Chronic Heart Failure</p>
Price Susanna	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>
Rosano Giuseppe M C	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Laboratories : Dyslipidaemia Vifor International : Iron Deficiency Menarini : Ischaemic heart disease / arterial hypertension Astra Zeneca : speakers fees</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Vifor International : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott Laboratories : Risk Factors and Prevention</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rosano Giuseppe M C	2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. Scientific Board of Heart Failure Policy Network
Ruschitzka Frank	2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Advisory Board Novo Nordisk : Advisory Board Stiftung Pfizer Forschungspreis : Consulting service Astra Zeneca : Grant to the University of Zurich: Postgraduate Course in Heart Failure Bayer : Grant to the University of Zurich: Postgraduate Course in Heart Failure Novartis : Grant to the University of Zurich: Postgraduate Course in Heart Failure Servier : Grant to the University of Zurich: Postgraduate Course in Heart Failure Abbott/St. Jude Medical : Grant to the University of Zurich: Postgraduate Course in Heart Failure Bayer : Speaker Fee Novartis : Speaker Fee Servier : Speaker Fee Boehringer Ingelheim : Speaker Fee Trama Solutions SL : Speaker Fee Medworld : Speaker Fee IMC / AstraZeneca : Speaker Fee, Advisory Board Research funding from healthcare industry under your direct/personal responsibility (to department or institution). concept medical : ABILITY Boston Scientific : ACURATE Amgen : Aging Heart Bayer : Aging Heart Vifor International : Aging Heart Roche Diagnostics : Aging Heart MSD : Aging Heart

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	<p>Boehringer Ingelheim : Aging Heart Sanofi Aventis : ALIROL09100 HAMILTON HEALTH SCIENCES : ARTESIA Biotronik : Biostream HF, Biostream ICM Sahajanand IN / Cruz HBR : Cardiovascular European Research IHF GmbH : CRUZ Senior Astrazeneca : DAPA-VOLVO Quintiles : DSE-EDO-04-1-EU Amgen : HAYMANNNS Study 20130296, ECARA 20150245 Novartis : HERITAGE CTQJ230A12001 Medtronic : Micra TM Registry, EV ICD Pivotal Boston Scientific : Multistars Novartis : PARAGON CLCZ696D2301 Kaneka Corporation : PMCF RAIDEN3 Berlin Heart GmbH : Projekt Berlin Heart V wave : Relieve-HF-Trial SSS International Clinical Research : RHEIA Kantar GmbH : SANTORINI Edwards Lifesciences : SAPIEN 3 Ultra, ENCIRCLE Abbott : Tako Tsubo Edwards Lifesciences : TAVI-PCI Novartis : VASCEND Bayer : XATOA, XATOC</p>
2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
	Bayer : Chronic Heart Failure
	Novartis : Chronic Heart Failure
	Roche Pharma : Chronic Heart Failure
	Stiftung Pfizer Forschungspreis : Chronic Heart Failure
	At the Limits Ltd. : Chronic Heart Failure
	Medical Education Global Solutions : Chronic Heart Failure
	Trama Solution : Chronic Heart Failure
	Research funding from healthcare industry under your direct/personal responsibility (to department or institution).
	concept medical : Ability, Chairman of the Department
	Boston Scientific : Acurate, Chairman of the Department
	Amgen : Aging Heart, Chairman of the Department
	Novartis : Aging Heart, Chairman of the Department
	Roche Diagnostics : Aging Heart, Chairman of the Department
	Novo Nordisk : Aging Heart, Chairman of the Department
	Sanofi Aventis : ALIROL09100, Chairman of the Department
	Boehringer Ingelheim : Anging Heart, Chairman of the Department
	HAMILTON HEALTH SCIENCES : Artesia, Chairman of the Department
	Amgen : ASCVD (Lpa) 20210057, Chairman of the Department
	Biotronik : CR021CHE001 & TA115 & HS061CHE001, Chairman of the Department
	IHF GmbH : CRUZ Senior, Chairman of the Department
	Astra Zeneca : DAPA-VOLVO, Sponsor
	Quintiles : DSE-EDO-04-14, Chairman of the Department
	Berlin Heart : Eval. endoth. funct. Heart, Chairman of the Department
	Novartis : Heritage CTQj230A12001, Chairman of the Department
	Novartis : Horizon/CTQJ230A12301, Chairman of the Department
	Innosuisse : INOCA, Chairman of the Department

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	<p style="text-align: center;">Type of Relationship with Industry</p> <p>Boston Scientific : ISROTH10196, Chairman of the Department Medtronic : Micra TM Registry, EV ICD Pivotal, Chairman of the Department Boston Scientific : Multistars, Chairman of the Department SORIN CRM SAS : OCTOPUS, Chairman of the Department V wave : Relieve-HF-Trial, Principal Investigator Edwards Lifesciences : SAPIEN 3 Ultra, Chairman of the Department Kantar GmbH : Satorini, Chairman of the Department MedAlliance : Selution DeNovo, Chairman of the Department Edwards Lifesciences : TAVI PCI, Chairman of the Department Edwards Lifesciences : TRISCEND, Chairman of the Department Novartis : VASCEND-LCZ, Investigator Bayer : XATOC, Chairman of the Department</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. The Department of Cardiology (University Hospital of Zurich/University of Zurich) reports educational- and/or fellowship grants from Abbott, Abiomed, Alexion, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, CSL, Daiichi Sankyo, Diatools, Edwards, Johnson/Johanson Biosense Webster, Kiniksa, Medtronic, MicroPort, Novartis, Pfizer/ Bristol Myers Squibb, Pfizer, RecorMedical, Roche, Sanofi, Sarstedt, Servier, SisMedical, Stromal, Zoll, VascularMedical, Vifor, WissenPlus. These grants do not impact on my personal remuneration.</p>
Skibelund Anne Kathrine	<p>2021 Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Nothing to be declared</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Abdel Ghany Mohamed	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Acute coronary syndrome Servier : Hypertension
	2022 Nothing to be declared
Abdullaev Timur	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology, Heart Failure Polpharma : Cardiology, Heart Failure
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Polpharma : Chronic Heart Failure
Agladze Vaja	2021 Nothing to be declared
	2022 Nothing to be declared
Aidargaliyeva Nazipa	2021 Nothing to be declared
	2022 Nothing to be declared
Alami Mohamed	2021 Declaration not submitted
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Sanofi Aventis : Hypertension Amgen : Other
Arbelo Elena	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Arbelo Elena	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)</p>
Bajraktari Gani	<p>2021 Nothing to be declared</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Krka Pharma : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Krka Pharma : Hypertension</p>
Bartunek Jozef	<p>2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Occlutech : Heart Failure Endotronix : Heart Failure CorVia : Heart Failure Vectorius : Heart Failure Enopace : heart failure Cardionomics : heart failure</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Occlutech : Device Therapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cardionomics : Acute Heart Failure Endotronix : Chronic Heart Failure Vectorius : Chronic Heart Failure Occlutech : Device Therapy Enopace : Device Therapy</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Bartunek Jozef	2022 Employment (including part time) in healthcare industry during the year for which you are declaring. Occlutech : consultant CMO, not directly employed
Bauersachs Johann	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Afib, Amyloidosis Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure Bayer : Afib, heart failure Bristol Myers Squibb : Afib, heart failure Amgen : CAD, Heart Failure Novartis : Heart Failure CVRx : Heart Failure CorVia : Heart Failure Cardior : Heart Failure Vifor International : heart failure, hyperkalemia Astrazeneca : heart failure, hyperkalemia Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Zoll Medical : Arrhythmia Abiomed : cardiogenic shock CVRx : Heart Failure

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Bauersachs Johann	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Acute Heart Failure Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF) Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure CVRx : Chronic Heart Failure Astrazeneca : Chronic Heart Failure Cardior : Chronic Heart Failure Norgine : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Roche Diagnostics : Atrial fibrillation, Co-Investigator Norgine : heart failure / iron deficiency, Principal Investigator Zoll Medical : heart failure, Co Investigator CVRx : heart failure, Investigator</p>
Borger Michael A	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Borger Michael A	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
Boskovic Aneta	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial fibrillation Astra Zeneca : Heart failure Boehringer-Ingelheim : Heart failure</p> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Atrial Fibrillation (AF) Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure</p>
Broch Kaspar	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiac amyloidosis Astra Zeneca : Heart failure Boehringer-Ingelheim : Heart failure Novo-Nordisk : Heart failure Pharmacosmos : Heart failure/intravenous iron</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Heart failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Broch Kaspar	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Pfizer : Myocardial Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Funding for investigator-initiated trial, Chief investigator Amgen : Funding for investigator-initiated trial, Investigator</p>
Buccheri Sergio	2021	Nothing to be declared
	2022	Nothing to be declared
Campbell Patricia	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart failure Boehringer-Ingelheim : Heart Failure Novartis : Heart failure Pfizer : Heart failure Vifor International : Heart failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Heart failure</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Clinical advisory board member for Pumping Marvellous UK HF charity</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Campbell Patricia	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure Vifor International : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I sit on the clinical advisory board of the UK Heart Failure Charity Pumping Marvellous</p>
Celik Ahmet	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure Boehringer-Ingelheim : heart failure Novartis : heart failure</p>
	2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>
Cerbai Elisabetta	2021	Nothing to be declared
	2022	Nothing to be declared
Chettibi Mohamed	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo-Nordisk : Investigator Select study</p>
	2022	Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Christodoulides Theodoros	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Dyslipidemia
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Risk Factors and Prevention Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Risk Factors and Prevention
Clark Andrew L	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pharmacosmos : Iron therapy Receipt of royalties for intellectual property. Oxford University Press : Book publishing Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Membership of BCS and BSH
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Pfizer : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Receipt of royalties for intellectual property. Oxford University Press : Chronic Heart Failure, Acute Heart Failure Employment (including part time) in healthcare industry during the year for which you are declaring. Hull University Teaching Hospitals NHS Trust : Cardiologist Membership or affiliation in political or advocacy groups working in the field of cardiology. British Cardiovascular Society; British Society for Heart Failure; Royal College of Physicians; ESC; British Society for Echocardiography; British Medical Association.

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : failure pharmacotherapy Abbott : Heart Failure Astra Zeneca : heart failure pharmacotherapy Bayer AG : heart failure pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Heart failure and oncology biomarkers Astra Zeneca : heart failure pharmacotherapy Novo Nordisk : Heart failure pharmacotherapy</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Roche Diagnostics : heart failure and oncology biomarkers Abbott : Heart Failure devices Astra Zeneca : heart failure pharmacotherapy Novo-Nordisk : heart failure pharmacotherapy Cardior GmbH : heart failure pharmacotherapy Ionis Pharmaceuticals, Inc : heart failure pharmacotherapy</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. President-elect of the Dutch Cardiac Society (NVVC)</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Roche Diagnostics : Biomarker experiments in the field of HF, Principal investigator Abbott : Clinical trial support, Principal investigator Boehringer-Ingelheim : Laboratory experiments in the field of HF, Principal investigator Novo-Nordisk : Laboratory experiments in the field of HF, Principal investigator Ionis pharmaceuticals : Laboratory experiments in the field of HF, Principal investigator Astrazeneca : Laboratory experiments in the field of HFpEF, Principal investigator Cardior GmbH : Laboratory experiments in the field of HFpEF, Principal investigator</p>
Donal Erwan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : amyloidosis Alnylam : amyloidosis Astra Zeneca : heart failure General Electric : imaging Abbott Vascular : valves</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Vascular : valves</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : valves</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Donal Erwan	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure General Electric : Echocardiography Pfizer : Myocardial Disease Alnylam : Myocardial Disease Abbott Vascular : Valvular Heart Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Vascular : Valvular Heart Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : corelab activities, corelab for Abbott</p>
Edelmann Frank	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure Boehringer-Ingelheim : heart failure Novartis : heart failure Vifor International : heart failure Merck Sharp & Dohme : heart failure Bayer Vital : heart failure Pharmacosmos : heart failure Actelion : pulmonary hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Servier : heart failure</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. German Centre for Cardiovascular Research, partner site Berlin, GER</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Edelmann Frank	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Actelion : Chronic Heart Failure Vifor International : Chronic Heart Failure Bayer Vital : Chronic Heart Failure Merck Sharp & Dohme : Chronic Heart Failure, Acute Heart Failure Pharmacosmos : Chronic Heart Failure, Acute Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Servier : Cohrot study: German HFpEF registry, Principal investigator</p>
El Neihoum Ali	2021	Nothing to be declared
	2022	Nothing to be declared
Faerber Gloria	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Edwards Lifesciences : Education and Heart Valve Abbott : Heart Failure</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Device Therapy</p>
Foscoli Marina	2021	Nothing to be declared
	2022	Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Franco Fatima	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Sacubitril in Heart failure wth reduced heart failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : ESC Congress 2022</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure</p>
Frantz Stefan	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Cardiology Bayer : Cardiology Boehringer-Ingelheim : Cardiology Daiichi Sankyo : Cardiology Novartis : Cardiology Pfizer : Cardiology Servier : Cardiology Vifor International : Cardiology Novo-Nordisk : Cardiology Amarin : Cardiology</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Frantz Stefan	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Siemens Healthcare : Cardiac Computed Tomography (CT) Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amarin : Interventional Cardiology Vifor International : Other Novo-Nordisk : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from Abbot, Abiomed, Amarin, Amgen, AstraZeneca, Bayer, Berlin-Chemie, Biotronik, Boehringer, Bristol-Myers Squibb, Boehringer, Daiichi Sankyo, Edwards, Lilly, Novartis, Pfizer, Sanofi-Aventis, Siemens, Vifor, Zoll : 19 items checked</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). see 2A : Clinical trials, IITs, investigator, etc.</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Deutsche Gesellschaft für Kardiologie</p>
Fras Zlatko	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes mellitus, anticoagulation Amgen : lipid treatment Sanofi Aventis : lipid treatment Novartis : lipids, heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : lipidology - lipoprotein (a)</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Fras Zlatko	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : HORIZON Trial; VICTORION-2P Trial, site PI; nat coord</p>
Goncalvesova Eva	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : amyloidosis Boehringer-Ingelheim : heart failure Novartis : heart failure Merck : heart failure Servier : heart failure, arterial hypertension Johnson & Johnson : pulmonary hypertension AOP Orphan Pharmaceuticals : pulmonary hypertension Amgen : secondary prevention Sandoz : Transplantation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Union for Healthy Heart (patients organisation)</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Goncalvesova Eva	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure Sandoz : Chronic Heart Failure Merck : Chronic Heart Failure Servier : Hypertension Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure AOP Orphan Pharmaceuticals : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Amgen : Risk Factors and Prevention</p>
Gonzalez-Costello Jose	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiac amyloidosis Alnylam : Cardiac amyloidosis Astra Zeneca : Heart failure Bayer : Heart failure Boehringer-Ingelheim : Heart failure Chiesi Pharma : Heart transplant Abbott : Left ventricular assist devices Zoll Medical : Sudden cardiac death</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Abbott : Advanced heart failure Astra Zeneca : Heart failure</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. President of the Spanish Heart Failure Association within the Spanish Society of Cardiology</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gonzalez-Costello Jose	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Chiesi Pharma : Chronic Heart Failure Pfizer : Myocardial Disease Alnylam : Myocardial Disease Zoll Medical : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure</p>
Hasin Tal	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : advisory board Boehringer-Ingelheim : advisory board on Dapagliflozin use in heart failure Boehringer-Ingelheim : speaker fee Sanofi Aventis : speaker fee</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Vectorious : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Pfizer : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Arterial Hypertension, Coronary Heart Diseases Egis Pharma : Arterial Hypertension, Dyslipidemia Novartis : Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Tricida Inc. : Chronic Kidney Disease</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Servier : Hypertension Egis Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Servier : RCT, national coordinator</p>
Heidecker Bettina	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer, Bayer, Sanofi-Aventis, Novartis : Amyloidosis, Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : Amyloidosis</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. I am in the Board of Directors of the Myocarditis Foundation: https://www.myocarditisfoundation.org/</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer, Bayer, Sanofi-Aventis, Novartis : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>
Ibanez Borja	<p>2021</p> <p>Nothing to be declared</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Ibanez Borja	2022	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
Ingimarsdottir Inga Jona	2021	Nothing to be declared
	2022	Nothing to be declared
Islamli Aysel	2021	Nothing to be declared
	2022	Nothing to be declared
James Stefan	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
James Stefan	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
Kamzola Ginta	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Merck Serono : Beta blockers Boehringer-Ingelheim : Diabetes and cardiovascular diseases/heart failure Astra Zeneca : Heart Failure Bayer : Heart failure Novartis : Heart failure, cardiomyopathies, myocarditis, valvular pathologies Servier : Prevention of stroke</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Sevier : EuroEcho 2021 online Novartis : Heart failure 2021 online</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Latvian Society of Cardiology</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kamzola Ginta	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure Novartis : Chronic Heart Failure, Interventional Cardiology Servier : Echocardiography, Atrial Fibrillation (AF), Stroke</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Bayer : Chronic Heart Failure Sevier : Echocardiography Novartis : Echocardiography, Arrhythmias, General, Valvular Heart Disease, Myocardial Disease, Chronic Heart Failure, Device Therapy</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Latvian Society of Cardiology</p>
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Kosztin Annamaria	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Boston Scientific : Heart Failure, Device treatment</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Heart Failure Device Treatment</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Kosztin Annamaria	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Boston Scientific : Device Therapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy</p>
Kusljugic Zumreta	2021	Nothing to be declared
	2022	Nothing to be declared
Lassus Johan Paul Eric	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Coronary artery disease, Heart Failure Astra Zeneca : Heart Failure Boehringer-Ingelheim : Heart Failure Vifor International : Heart failure Pfizer : Oral anticoagulants</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Pfizer : Myocardial Disease</p>
Lindmark Krister	2021	Nothing to be declared
	2022	Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Malek Filip	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : antithrombotic therapy Servier : arterial hypertension, prevention of cardiovascular diseases Astra Zeneca : heart failure treatment Boehringer-Ingelheim : heart failure treatment Novartis : heart failure treatment Swixx Biopharma : iron deficit replacement in heart failure Organon : treatment and prevention of tromboembolic events Herbacos Recordati : treatment of heart failure</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Swixx Biopharma : Acute Heart Failure Bayer : Atrial Fibrillation (AF), Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Manintveld Olivier	<p>2021 Nothing to be declared</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p>
Masip Josep	<p>2021 Nothing to be declared</p>
	<p>2022 Nothing to be declared</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
Mentz Robert	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : HF Boehringer-Ingelheim : HF Novartis : HF Merck Sharp & Dohme : HF Zoll Medical : HF Pharmacosmos : HF Windtree : HF Abbott : MCS
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Acute Heart Failure Bayer : Acute Heart Failure Novartis : Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Merck Sharp & Dohme : Chronic Heart Failure Zoll Medical : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Windtree : Chronic Heart Failure

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mihaylova Borislava	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	<p>2022</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Milicic Davor	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Novo-Nordisk : Antidiabetics</p> <p>Alcaloid AD Skopje : Antihypertensive medications</p> <p>PLIVA : Antihypertensive medications</p> <p>Krka Pharma : Antihypertensives</p> <p>Astra Zeneca : Antithrombotics in ACS</p> <p>Novartis : ARNI</p> <p>Roche Diagnostics : Biomarkers</p> <p>Abbott : LVAD</p> <p>Servier : Microvascular angina</p> <p>Bayer : NOACs</p> <p>Pfizer : NOACs</p> <p>Boehringer-Ingelheim : NOACs, SGLT-2 inhibitors</p> <p>Amgen : PCSK-9 inhibitors</p> <p>Sanofi Aventis : PCSK-9 inhibitors</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Milicic Davor	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Pharmacology and Pharmacotherapy Astra Zeneca : Pharmacology and Pharmacotherapy Bayer : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Pfizer : Pharmacology and Pharmacotherapy Servier : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy Krka Pharma : Pharmacology and Pharmacotherapy PLIVA : Pharmacology and Pharmacotherapy Berlin chemie menarini : Pharmacology and Pharmacotherapy Swixx : Pharmacology and Pharmacotherapy</p>
Mirrakhimov Erkin	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p>
Moller Jacob Eifer	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Mechanical Circulatory Support Boehringer-Ingelheim : SGLT2i in heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abiomed : Mechanical circulatory support</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Moller Jacob Eifer	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Acute Cardiac Care Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abiomed : Principal investigator in Danger Shock randomized trial in cardiogenic shock testing mechanical circulatory support (Impella), Principal investigator</p>
Moore Alice May	2021	Nothing to be declared
	2022	Nothing to be declared
Mullens Wilfried	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : consultancy fee Vifor International : research grant Abbott : speakers fee Boston Scientific : speakers fee Novartis : speakers fee</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Training and Education Astra Zeneca : Training and Education Medtronic : Training and Education Novartis : Training and Education Biotronik : Training and Education Novo-Nordisk : Training and Education dynacom : Training and Education</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Nessler Jadwiga	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Berlin Chemie AG : Heart Failure Roche Diagnostics : Heart Failure Servier : Hypertension, Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Servier : Heart Failure</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Representative of Main Bord of Polish Cardiac Society in Heart Failure and Palliative Care</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Chronic Heart Failure Berlin Chemie AG : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Nessler Jadwiga	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Representative of Main Board of Polish Cardiac Society in Heart Failure and Palliative Care
Neubeck Lis	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),
Nielsen Jens Cosedis	2021	Nothing to be declared
	2022	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.
Oliva Fabrizio	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure Bayer : heart failure Novartis : heart failure Orion : heart failure Vifor International : heart failure
	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure
Oudeh Abdunnasser	2021	Nothing to be declared
	2022	Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
Paul Matthias	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Heart Failure (consultancy, advisory board and speaker fees) Servier : Heart Failure (speaker fees) Vifor International : Heart failure (speaker fees, consultancy) Astra Zeneca : SGLT2-Inhibitors / Heart Failure (consultancy, advisory board fees) Boehringer-Ingelheim : SGLT2-Inhibitors / Heart Failure (consultancy, advisory board fees)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure (consultancy, advisory board fees) Boehringer-Ingelheim : Heart Failure (consultancy, advisory board fees) Novartis : Heart Failure (consultancy, advisory board fees)</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : congress / travel costs</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Paul Matthias	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Chronic Heart Failure Vifor International : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Chronic Heart Failure</p>
Pavo Noemi	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p>
Poder Pentti	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Heart Failure</p> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer Ingelheim : Chronic Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Bayer : anticoagulation</p> <p>Vifor International : heart failure (HF)</p> <p>Amgen : HF</p> <p>Astra Zeneca : HF</p> <p>Novartis : HF</p> <p>Pfizer : HF</p> <p>Servier : HF</p> <p>Impulse Dynamics : HF</p> <p>Abbott Vascular : HF</p> <p>Respicardia : HF</p> <p>Berlin-Chemie : HF</p> <p>Renal Guard : HF</p> <p>Boehringer-Ingelheim : hf, anticoagulation</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : Chronic Heart Failure, Acute Heart Failure</p> <p>Bayer : Chronic Heart Failure, Acute Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure</p> <p>Novartis : Chronic Heart Failure, Acute Heart Failure</p> <p>Pfizer : Chronic Heart Failure, Acute Heart Failure</p> <p>Servier : Chronic Heart Failure, Acute Heart Failure</p> <p>Vifor International : Chronic Heart Failure, Acute Heart Failure</p> <p>Abbott Vascular : Chronic Heart Failure, Acute Heart Failure</p> <p>Berlin-Chemie : Chronic Heart Failure, Acute Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Popescu Bogdan Alexandru	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulants Pfizer : Anticoagulants Johnson & Johnson : Cardiooncology Novartis : Heart failure GE Healthcare : Imaging
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Other Novartis : Risk Factors and Prevention
Pouleur Anne-Catherine	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Speaker fee, Advisory Board Bayer : Speaker fee, Advisory Board Boehringer-Ingelheim : Speaker fee, Advisory Board Pfizer : Speaker fee, Advisory Board
	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Pfizer : Chronic Heart Failure Vifor International : Chronic Heart Failure
Prescott Eva	2021	Nothing to be declared
	2022	Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rakisheva Amina	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
Rocca Bianca	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator
Rossello Francisco Javier	2021 Nothing to be declared
	2022 Nothing to be declared

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Roubille Francois	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. NovoNordisk : Diabetes Sanofi Aventis : Dyslipidemia Mylan : dyslipidemia Abbott : Heart Failure Boehringer-Ingelheim : Heart failure Novartis : heart failure Pfizer : heart failure Bayer AG : Heart Failure Abiomed : Heart failure Astra-Zeneca : Heart failure Air liquide : HEart failure Amgen Inc : HEart failure, dyslipidemia Servier : Hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Roubille Francois	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : Acute Cardiac Care Amgen Inc : Acute Coronary Syndromes NovoNordisk : Acute Coronary Syndromes Abiomed : Acute Heart Failure Abbott : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure Bayer AG : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Air liquide : Chronic Heart Failure Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Mylan : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Sade L Elif	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : speaker honorarium fee to the University of Baskent</p> <hr/> <p>2022</p> <p>Nothing to be declared</p>
Schaubroeck Hannah	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Impella Boehringer-Ingelheim : SGLT2-inhibitors - cardiorenal syndrome</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). GETINGE : Mechanical circulatory support (MCS)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. board member of BIWAC</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Schaubroeck Hannah	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Acute Heart Failure Abiomed : Acute Heart Failure, Acute Cardiac Care, Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). GETINGE : MCS national registry (BIWAC), principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ISICEM faculty 2023 (International Symposium on Intensive Care and Emergency Medicine) ESICEM member (European society of Intensive Care Medicine)</p>
Schulze Christian	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Acute Heart Failure, Cardiogenic Shock Berlin Chemie AG : General Cardiology Bayer Healthcare : Heart Failure Novartis : Heart Failure, Metabolism Boehringer-Ingelheim : Heart Failure, Metabolism, Investigator-initiated study Boston Scientific : Structural heart disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boston Scientific : Structural heart disease</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : 6 items checked Bayer Healthcare : 6 items checked Berlin Chemie AG : Acute Coronary Syndromes, Acute Cardiac Care Abiomed : Acute Heart Failure, Acute Coronary Syndromes Boston Scientific : Atrial Fibrillation (AF), Device Therapy Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Shuka Naltin	2021	Nothing to be declared
	2022	Nothing to be declared
Srbinovska-Kostovska Elizabeta	2021	Nothing to be declared
	2022	Nothing to be declared
Stavrati Alexia	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : ATTR amyloidosis CSL Behring : CORONARY ARTERY DISEASE Astra Zeneca : HEART FAILURE Novartis : HEART FAILURE Boehringer-Ingelheim : HEART FAILURE, ATRIAL FIBRILLATION Medtronic : Implantable Carciac monitors for Syncope</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : FOR NATIONAL CARDIOLOGY CONGRESS. OCTOBER 2021</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. CSL Behring : Acute Coronary Syndromes Bayer : Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Other Pfizer : Other Servier : Other</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Stojisic-Milosavljevic Anastazija	2021	Nothing to be declared
	2022	Nothing to be declared
Tessitore Elena	2021	Nothing to be declared
	2022	Nothing to be declared
Tokmakova Mariya	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Cardiology Boehringer-Ingelheim : Cardiology Novartis : Cardiology, dyslipidemia
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Pharmacology and Pharmacotherapy Novartis : Chronic Heart Failure, Risk Factors and Prevention, Pharmacology and Pharmacotherapy Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes Servier : Hypertension, Pharmacology and Pharmacotherapy Krka Pharma : Hypertension, Risk Factors and Prevention Egis Pharma : Hypertension, Risk Factors and Prevention, Cardiovascular Disease in Special Populations Berlin Chemie AG : Pharmacology and Pharmacotherapy Novo-Nordisk : Risk Factors and Prevention

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Vifor International : comorbidities in Heart Failure Pharma Nord : selenium supplements in HF</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : amyloidosis Novo-Nordisk : diabetes and heart failure Pharmacosmos : iron deficiency Vifor International : iron deficiency and hyperkalemia Novartis : Sacubitril/valsartan Boehringer-Ingelheim : sglT2 inhibitors</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : amyloidosis Astra Zeneca : drugs for heart failure Pharma Nord : food supplements Vifor International : iron deficiency and hyperkalemia</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Vifor International : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure Pharmacosmos : Chronic Heart Failure Bridge bio : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Vifor International : iron deficiency in heart failure, PI Pharma Nord : micronutrient deficiencies , PI Astra Zeneca : Novel treatment target in genetic cardiomyopathy, PI Pfizer : research on amyloidosis, PI</p>
Van Gelder Isabelle C	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Atrial fibrillation stroke prevention Boston Scientific : Atrial fibrillation Medtronic : Atrial fibrillation Pfizer : Atrial fibrillation Roche Diagnostics : Atrial fibrillation</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : Atrial fibrillation</p> <hr/> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Stroke</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : RACE V AF prgression study, principle investigator</p>

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Van Heetvelde Mattias	2021	Nothing to be declared
	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. ESC Patient Forum member
Vataman Eleonora	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Egis Pharma : consultancy Berlin Chemie AG : speaker fee
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Egis Pharma : Other Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Voronkov Leonid	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Speakers fees Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Consultancy Travel and meeting support from healthcare industry, independent of the above activities. Krka Pharma : ESC Congress travel grant
	2022	Nothing to be declared
Vrints Christiaan Jm	2021	Nothing to be declared
	2022	Nothing to be declared
Wilhelm Matthias	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : CV drugs Novartis : CV drugs Boehringer-Ingelheim : CV drugs

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wilhelm Matthias	2021 Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Foundation board member Swiss Heart Foundation
	2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Foundation Board Member Swiss Heart Foundation
Witkowski Adam	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy
Zakhama Lilia	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Hikma : heart failure Hôpital des Forces de la Sécurité Intérieure : heart failure Servier : hypertension

2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Zakhama Lilia	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : European Society of Cardiology</p>
Zaliaduonyte Diana	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : speaker Boehringer-Ingelheim : speaker Novartis : speaker</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure Byer : Chronic Heart Failure Bioringer Ingelheim : Chronic Heart Failure</p>
Zeppenfeld Katja	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology</p> <hr/> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Arbelo Elena	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Renal disease
	2022	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
Borger Michael A	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy
	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
Buccheri Sergio	2021	Nothing to be declared
	2022	Nothing to be declared
Ibanez Borja	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ibanez Borja	<p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
Mihaylova Borislava	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>
Mindham Richard	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p>
Nielsen Jens Cosedis	<p>2021</p> <p>Nothing to be declared</p> <hr/> <p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Pasquet Agnes A	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
Prescott Eva	<p>2021 Nothing to be declared</p>
	<p>2022 Nothing to be declared</p>
Rakisheva Amina	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p>
Rocca Bianca	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p>
Rossello Francisco Javier	<p>2021 Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	2022	Nothing to be declared
Vaartjes Ilonca	2021	Nothing to be declared
	2022	Nothing to be declared
Vrints Christiaan Jm	2021	Nothing to be declared
	2022	Nothing to be declared
Witkowski Adam	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
Zeppenfeld Katja	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology</p>
	2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>